Vitality Biopharma Advances Cannabosides for Treatment of …

LOS ANGELES, CA–(Marketwired – Jul 27, 2016) – Vitality Biopharma, Inc. (OTCQB: STVFD) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced updates to its clinical development plans including the advancement of cannabosides for the treatment of inflammatory bowel disease. 

Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation. 

Independent clinical trial results suggest that

... read more at: